The method of choice for the determination of the CK-MB isoenzyme is the antibody-inhibition procedure (1-2). CK-MB is the usual isoenzyme found in human serum. Its release is accepted as one of the best indicators of myocardial necrosis (3). The Technicon RA-1000 analyzer is easy to operate and well-suited for enzymatic assays.
unmodified).
The RA-1000 program for CK-MB isoenzyme was used with blank correction and the initial steps of sample and first-reagent additions were replaced by sham operations (4% and 70% minimum acceptable values, respectively). The required antibody-inhibition period of 10 min was satisfied with incubation periods of 6 mm outside and about 4 miii within the RA-1000 instrument (A1 delay of 30 s and A2 delay of 3 mm 45 s).
We first added the sample (20 giL) and the first reagent (500 L) manually to the RA-1000 cuvettes, and then incubated the mixture for the specified time. We performed the manual-ultraviolet procedure, as described elsewhere (2) , with the antibody-incubation step taking place in a temperature-controlled cuvette compartment. We tested reproducibility at enzyme activities between 8 and 150 U/L and found CVs of 1.5% to 9.4%; inter-day CVs for the BMC commercial control were also assessed and found to be 3%. We found good correlation (r = 0.89) between the two procedures (Figure 1 ). This semi-automated procedure simplifies estimation of CK-MB activity and also increases the reliability and speed as compared with the manual-ultraviolet method. We have used the procedure extensively in the emergency and intensive-care areas during the past three years with satisfactory results where rapid confirmation of myocardial infarction was essential. in predicting whether prolonged apnea may take place after administration of the widely used anaesthetic, succinylcholine (SCh), a short-acting muscle relaxant. Although decreases in this activity owing to an inherited enzyme abnormality or an acquired condition are associated with most cases of prolonged apnea, subjects with the "usual" (moat common) ChE phenotype also may encounter SCh apnea (1-3) .
References
We determined the reference interval for ChE activity in 150 healthy blood donors (75 women, 75 men), measuring ChE activity manually by a Selected Method (4), with propionylthiocholine as substrate. Because the frequency distribution of ChE activity in these subjects was not normal (gaussian) but log-normal (the histograms were positively skewed in both groups), we calculated the reference intervals by using the logarithms of the measurements; the reference intervals for women and men were 4.61-11.0 kUIL and 5.3-11.3 kU/L, respectively. This difference between groups was statistically significant, but not strongly so (0.025 <P < 0.05). Combining the data for the two groups gave a reference interval of 4.94-11.23 kU/L or about 5.0-11.0 kU/L.
The decision (cutoff) value of ChE activity for SCh apnea was calculated as log! -3 log SD, or 4.0 kU/L, whereas Diets et al. (4) used! -2.5 SD for this value. The ranges for the dibucame and fluoride numbers for the "usual" phenotype were 78-90 and 75-82, respectively. SCh, 1 mg/kg, was given intravenously to our surgical patients in the gastroenterology and urology operating room of our hospital, and the duration of action (the time from cessation of administering SCh to recurrence of spontaneous 
FIg. 1. Correlation of ChE activity with (fop)
the ratio of duration of action to activity, and (bottom) the logarithmof the ratio of duration of action to actMty respiration) was recorded. The ChE activities and phenotypes of all patients were determined. The samples with dibucaine and fluoride numbers less than 78 and 75, respectively, were discarded, so that only the subjects with UU phenotype (143 patients) were considered. Of these subjects, 33 patients (23%) had ChE activities <5.0 kUIL, and 22 (15.4%) had less than the cutoff value, 4.0 kU/L, owing to an acquired condition such as metastatic or primary carcinomas of the hepatobiliary, gastrointestinal, and (or) urinary system; gastric or duodenal ulcers; or malnutrition and malabsorption syndromes.
In these 143 patients we found a weak negative correlation between ChE activity (x) and the duration of action (y) of SCh: r = -O.55,y = -1.81x + 26.58. In contrast, as shown in Figure 1 , the correlation between activity and the logarithm of the ratio of duration of action to activity was more significant: Etofenamate has been quantified by gas chromatography (1) or by fluorimetry after thin-layer chromatography (2). Here we describe a simple HPLC method for determining etofenamate and its metabolite flufenamic acid in plasma and in tissues.
Plasma. To 1 mL of blood add 5 pL of an equimolar solution of etofenamate and flufenamic acid (used concentrations see below) in dimethyl sulfoxide. Next add 5 mL of an equivolume mixture of acetonitrile/methanol and centriliige (15 mm, 4000 x g). Resuspend the supernate in 5 mL of the acetonitrile/methanol solvent and re-centrifuge. Combine the supernates, dilute them with 100 mL of water, then pass them through an octadecyl reversed-phase extraction column (6 mL; Baker no. 70206) that has been previously washed successively with 10 mL of methanol, 5 mL of water, and 5 mL of a 1 g/L EDTA solution. After washing the column with two 5-mL portions of water, elute the adsorbed substances with 3 mL of methanol. Add 5 mL of water to the eluate and inject 2 mL into a 250 x 4 nun column packed with Nucleosil 7 C15 (Macherey & Nagel, D#{252}ren, F.R.G.).
Under the conditions used (flow rate 1 mL/min, detection 286 mn) no transformation of etofenamate to flufenamic
